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This editorial refers to ‘Rapid and highly efficient inducible
cardiac gene knockout in adult mice using AAV-mediated ex-
pression of Cre recombinase’ by S. Werfel et al., pp. 15–23,
this issue.
Knockout mice have revolutionized our ability to conduct biomedical
research and no area has benefited more than cardiovascular disease.
The knockout (or genetic deletion) of (a) specific gene(s) has provided
a clearer understanding of the roles a gene plays in development, normal
physiology, and in responses to injury, vasomotor regulation, and excita-
tion/contraction coupling to name a few. These advances notwithstand-
ing, the utility of traditional knockoutmice can be limited in cases where
the gene deletion causes embryonic lethality, or when a tissue-specific
knockout is desired to avoid having off-target effects limit the study.
The application of Cre-lox technology to transgenesis has provided a
powerful tool in helping investigators create tissue-specific knockouts.1
TheCre-lox strategy requires the breeding of two separate lines of gen-
etically manipulatedmice: ‘floxed’ mice in which the gene of interest has
been flanked by two loxP sites using ‘knock-in’ techniques, and another
line of transgenic mice in which a tissue-specific promoter is used to
drive the expression of Cre-recombinase. By crossing these two
strains, mice are obtained in which tissue-specific expression of Cre
results in deletion of the gene of interest due to the action of the
Cre-recombinase enzyme that excises the genomic region flanked by
the loxP sites. The deletion is tissue-specific because it can only occur
in tissues where Cre is expressed. In a further refinement of this
system, the Cre-recombinase has been made tamoxifen-inducible by
adding two modified oestrogen receptor (MER) ligand-binding
domains on either end of the fusion protein.2 The temporal control
over gene deletion provided by this MER-Cre-MER system enables
investigators to overcome embryonic lethality, to study gene function
during different phases of a disease process, and to conduct lineage-
tracing studies.
In the current article, Werfel et al.3 employed a one-two punch with
AAV9 and Cre to expedite cardiac gene inactivation in adult mice by
using adeno-associated viral vectors of serotype 9 (AAV9) to deliver
Cre-recombinase under the control of a cardiac-specific promoter
(cTnT). Although this approach still requires the generation of ‘floxed’
mice, thesemice can then be treatedwith a simple intravenous injection
of the AAV9 vector expressing Cre-recombinase, as opposed to the
typical strategy of crossing with a transgenic line expressing Cre. Using
the AAV9 approach, gene knockout is virtually complete and the
timing of recombination can be chosen by the investigator to meet the
needs of the experimental design. One can appreciate how such tem-
poral control could be superimposed upon animal models of diseases
such as diabetes or hypertension without the need for additional (i.e.
tamoxifen) treatment since even moderate doses of tamoxifen in
aMHC-MerCreMer mice induce a DNA damage response, leading to
cardiac dysfunction, fibrosis, and even failure at higher doses.4 The
authors also nicely show that the human cTnT promoter provides
better cardiac specificity than the alpha-myosin heavy chain (Myh6) pro-
moter and they demonstrate proof of principle by using AAV9/
MER-Cre-MER to knockout the gene encoding the serum response
factor (SRF) in adult mice.
As noted by the authors, advantages of the AAV-cTnT-Cre approach
when compared with conventional transgenesis include the reduction in
breeding needed for conditional knockout experiments, given that at
least two rounds of mating are required to cross a Cre-expressing line
with homozygous floxed mice. A potential disadvantage of this approach
is the low level of recombination detected in off-target tissues including the
liver, lung, and spleen.As notedby the authors, off-targetCre expression in
the liver can be suppressed by incorporating miR-122 sites behind the Cre
cDNA to selectively destabilize Cre mRNA in the liver.5 Other limitations
might include the moderate dose of AAV9 vector required to achieve
Cre-mediated excision in 80–90% of cardiomyocytes, but this is balanced
against the negative effects of tamoxifen in the hearts.
One should note that the generalizability of the AAV/Cre approach
involving IV injection to other tissues depends greatly on the tissue
tropismof theAAV serotype combinedwith the specificity of the tissue-
specific promoter. The combination of the liver-tropic AAV8 capsid and
the liver-specific thyroxine-binding globulin (Tbg) promoter has previ-
ouslybeenused to specificallydeletefloxedHdac3 in the liver.6 Similarly,
one can predict that the combination of muscle-tropic AAV9 and the
muscle-specificCK6 promoter7would provide for the specific targeting
of Cre to skeletal myofibers, particularly in ischaemic hindlimbs.8
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As noted by Werfel et al.,3 the combination of AAV and Cre has
already proven very powerful in the field of neuroscience, where the
local delivery of AAV by stereotactic injection has been used for over
a decade for optogenetic studies and for tracking neural connectivity.
Thus, in the brain, local injection long ago provided the tissue specificity
that in the heart can now be achieved by intravenous injection of AAV9
carrying cardiac-specific promoters. Because of this, the utility of com-
bining AAV with Cre recombination has been more thoroughly
explored in the brain than in the heart, resulting in such refinements
as the reciprocal arrangement in which transgenic mice expressing cell-
specific Cre mediate the recombination of floxed alleles delivered via
AAV.One visually obvious example of this can be found in the Brainbow
system.9 Another innovation in AAV-mediated recombination involves
using the Cre-LoxP and Flp-FRP systems in combination,9 which could
potentially allow for multicolour lineage tracing in the appropriate indi-
cator mice.
Given the recent progress in using gene delivery to promote cardiac
regeneration,10,11 it is not difficult to imagine AAV-mediated lineage
tracking of fibroblasts that have been transdifferentiated into cardio-
myocytes, epicardial progenitor cells programmed to contribute to
cardiac regeneration, or cardiomyocytes that have been reprogrammed
to replicate. With the right combination of targeted AAV vectors
expressing the appropriate regulatory factors in tandem with Cre, Flp,
and other recombinases, it may one day be possible to determine the
relative contributions of each strategy to promoting the regeneration
of regions of myocardium that had previously been infarcted, as illu-
strated in Figure 1. Given that research efforts are already underway to
downsize the CRISPR/Cas9 gene editing system so that it can be pack-
aged into AAV capsids,12 the future indeed looks quite bright for AAV-
mediated gene editing and recombination!
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Figure 1 Stylized depiction of what fully regenerated myocardium
might resemble after successful cardiac regeneration of a myocardial
infarct using AAV-mediated gene therapy coupled with the expression
ofmultiple recombinases. Each colour indicates a lineageof cells result-
ing from a particular regenerative strategy (fibroblast transdifferentia-
tion, cardiomyocyte replication, etc.). The transgenic mice used for
such a demonstration would need to carry multiple genes encoding
fluorescent proteins flanked by the target recognition sites for each
recombinase. Modified from Prasad et al.13
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